Bolt Biotherapeutics (NASDAQ:BOLT) Releases Quarterly Earnings Results, Beats Expectations By $1.43 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) released its quarterly earnings results on Thursday. The company reported ($2.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.68) by $1.43, FiscalAI reports. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.

Bolt Biotherapeutics Price Performance

NASDAQ:BOLT traded down $0.35 during mid-day trading on Thursday, hitting $5.91. 177,672 shares of the company’s stock traded hands, compared to its average volume of 92,765. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The company has a market cap of $11.41 million, a PE ratio of -0.36 and a beta of 0.85. The firm’s 50 day simple moving average is $4.54 and its 200 day simple moving average is $4.52. Bolt Biotherapeutics has a 1 year low of $3.10 and a 1 year high of $7.78.

Insider Activity

In other Bolt Biotherapeutics news, major shareholder Coastlands Capital Lp purchased 50,000 shares of the stock in a transaction dated Monday, November 9th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the completion of the transaction, the insider directly owned 462,416 shares of the company’s stock, valued at $2,950,214.08. This trade represents a 12.12% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO William Quinn sold 9,132 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the sale, the chief executive officer owned 25,384 shares in the company, valued at $82,244.16. This represents a 26.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,584 shares of company stock worth $128,361 in the last ninety days. Insiders own 9.40% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.